Skip to main content
Premium Trial:

Request an Annual Quote

Amarantus Licenses Power3 Test for Parkinson's Disease

NEW YORK (GenomeWeb News) – Amarantus BioSciences today said that it has licensed exclusive, worldwide rights from Power3 Medical Products to a test for Parkinson's disease diagnosis.

Power3's NuroPro Blood Test has been developed for the early detection of neurodegenerative diseases. It monitors the concentration of 57 protein markers in blood serum that have been linked to neurodegeneration, and according to the firms, can accurately detect and distinguish Alzheimer's disease, ALS, and Parkinson's disease. The test is being developed to help assist physicians in diagnosing disease and monitoring progression, the firms added.

Sunnyvale, Calif.-based Amarantus, which is developing a disease-modifying protein therapeutic for treatment of Parkinson's disease, paid a $25,000 exclusivity fee in common stock in November and will issue to Power3 $475,000 worth of common stock. In addition, it signed an option to purchase all of the Parkinson's Disease IP owned by Power3 for $500,000 worth of common stock and maintains a right of first refusal to acquire the balance of the NuroPro platform for Alzheimer's disease, ALS, and all other neurodegenerative diseases.

The terms of the license is one year and is renewable upon mutual written agreement between the firms.

"Now that we will be able to tailor our therapeutic development pathway towards a companion diagnostic product that we control, Amarantus is positioned to build a strategic advantage over competitors as the execution of our clinical and regulatory strategy continues to advance [Mesencephalic-Astrocyte-derived Neurotrophic Factor] as a disease-modifying treatment for Parkinson's disease," Gerald Commissioning, president and CEO of Amarantus BioSciences, said in a statement.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.